Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Leukemia

Volumn 30, Issue 2, 2016, Pages 464-472

  Peter, B ^a   Winter, G E ^b   Blatt, K ^a   Bennett, K L ^b   Stefanzl, G ^a   Rix, U ^b,c   Eisenwort, G ^a   Hadzijusufovic, E ^a   Gridling, M ^b   Dutreix, C ^d   Hoermann, G ^a   Schwaab, J ^e   Radia, D ^f   Roesel, J ^d   Manley, P W ^d   Reiter, A ^e   Superti Furga, G ^b   Valent, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 52421; CGP 62221; DRUG METABOLITE; HISTAMINE; IMMUNOGLOBULIN E RECEPTOR; MIDOSTAURIN; PROTEIN KINASE FES; PROTEIN KINASE SYK; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; STAUROSPORINE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; AGGRESSIVE SYSTEMIC MASTOCYTOSIS; ARTICLE; BASOPHIL; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE COURSE; DRUG COMPETITION; FEMALE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IC50; INDOLENT SYSTEMIC MASTOCYTOSIS; LEUKEMIA CELL LINE; MALE; MAST CELL; MIDDLE AGED; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEOMICS; SYSTEMIC MASTOCYTOSIS; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; MASTOCYTOSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; AGED; BASOPHILS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HISTAMINE RELEASE; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; STAUROSPORINE;

EID: 84959359802     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.242     Document Type: Article

References (48)

1. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695-717.
2. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55: 419-432.
3. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3: 497-516.
4. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543-551.
5. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007; 74: 121-132.
6. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
7. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312-314.
8. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609-1614.
9. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357-364.
10. Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 127: 110-114.
11. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635-641.
12. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81: 677-690.
13. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
14. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-232.
15. Gonzälez-De-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011; 3: 637-651.
16. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007; 119: 1550-1551.
17. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3-11.
18. Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-Defined systemic mastocytosis in adults. Haematologica 2008; 93: 6-9.
19. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010; 116: 5812-5817.
20. Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865-2870.
21. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752-759.
22. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286-291.
23. Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816Vmutated oncogenic variant of KIT. Haematologica 2007; 92: 1451-1459.
24. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012; 120: 799.
25. Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011; 35: 1143-1152.
26. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-Type or mutated c-kit. Exp Hematol 2003; 31: 686-692.
27. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15: 17-28.
28. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721-724.
29. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
30. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the global D2201 trial. Blood 2013; 122: 106.
31. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, et al. The effects of dasatinib on IgE receptor-Dependent activation and histamine release in human basophils. Blood 2008; 111: 3097-3107.
32. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-Dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009; 39: 1711-1720.
33. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin Oncol 2001; 19: 1485-1492.
34. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60.
35. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006; 108: 3477-3483.
36. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-Drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol 2013; 72: 1223-1234.
37. Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H. Dose- and time-Dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. J Clin Pharmacol 2008; 48: 763-775.
38. Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989; 73: 1778-1785.
39. Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol 2014; 95: 95-104.
40. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345-355.
41. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-4063.
42. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283-13288.
43. Fernbach NV, Planyavsky M, Müller A, Breitwieser FP, Colinge J, Rix U, et al. Acid elution and one-Dimensional shotgun analysis on an Orbitrap mass spectrometer: an application to drug affinity chromatography. J Proteome Res 2009; 8: 4753-4765.
44. Bennett KL, Funk M, Tschernutter M, Breitwieser FP, Planyavsky M, Ubaida Mohien C, et al. Proteomic analysis of human cataract aqueous humour: comparison of one-Dimensional gel LCMS with two-Dimensional LCMS of unlabelled and iTRAQ (R)-labelled specimens. J Proteomics 2011; 74: 151-166.
45. Hoermann G, Cerny-Reiterer S, Perné A, Klauser M, Hoetzenecker K, Klein K, et al. Identification of oncostatin M as a STAT5-Dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am J Pathol 2011; 178: 2344-2356.
46. Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 2010; 38: 744-755.
47. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 2007; 110: 2593-2599.
48. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-4276.